Details for New Drug Application (NDA): 207968

✉ Email this page to a colleague

NDA 207968 describes JADENU SPRINKLE, which is a drug marketed by Novartis and is included in one NDA. It is available from one supplier. Additional details are available on the JADENU SPRINKLE profile page.

The generic ingredient in JADENU SPRINKLE is deferasirox. There are twenty drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the deferasirox profile page.

Summary for 207968

Tradename:	JADENU SPRINKLE
Applicant:	Novartis
Ingredient:	deferasirox
Patents:	0

Pharmacology for NDA: 207968

Mechanism of Action	Cytochrome P450 1A2 Inhibitors Cytochrome P450 2C8 Inhibitors Cytochrome P450 3A4 Inducers Iron Chelating Activity

Suppliers and Packaging for NDA: 207968

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
JADENU SPRINKLE	deferasirox	GRANULE;ORAL	207968	NDA	Novartis Pharmaceuticals Corporation	0078-0713	0078-0713-15	30 PACKET in 1 CARTON (0078-0713-15) / 1 GRANULE in 1 PACKET (0078-0713-19)
JADENU SPRINKLE	deferasirox	GRANULE;ORAL	207968	NDA	Novartis Pharmaceuticals Corporation	0078-0720	0078-0720-15	30 PACKET in 1 CARTON (0078-0720-15) / 1 GRANULE in 1 PACKET (0078-0720-19)

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	GRANULE;ORAL			Strength	90MG
Approval Date:	May 18, 2017	TE:	AB	RLD:	Yes

Profile for product number 002

Active Rx/OTC/Discontinued:	RX	Dosage:	GRANULE;ORAL			Strength	180MG
Approval Date:	May 18, 2017	TE:	AB	RLD:	Yes

Profile for product number 003

Active Rx/OTC/Discontinued:	RX	Dosage:	GRANULE;ORAL			Strength	360MG
Approval Date:	May 18, 2017	TE:	AB	RLD:	Yes

Expired US Patents for NDA 207968

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novartis	JADENU SPRINKLE	deferasirox	GRANULE;ORAL	207968-001	May 18, 2017	⤷ Sign Up	⤷ Sign Up
Novartis	JADENU SPRINKLE	deferasirox	GRANULE;ORAL	207968-003	May 18, 2017	⤷ Sign Up	⤷ Sign Up
Novartis	JADENU SPRINKLE	deferasirox	GRANULE;ORAL	207968-002	May 18, 2017	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.